Drugs / Thrombexx
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT01960569 Comparator | Oct 2013 → Jan 2014 | external hirudiniasis | MinaPharm Pharmaceuticals | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Thrombexx | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01960569 ↗ |
| Action | Inhibit | “Hirudin is the most potent direct thrombin inhibitor” PMID 30046714 ↗ Nov 2017 |
| Modality | Protein / enzyme biologic | “topically administered recombinant hirudin gel” PMID 30046714 ↗ Nov 2017 |
| Route | Topical | “topically administered recombinant hirudin gel” PMID 30046714 ↗ Nov 2017 |